Literature DB >> 11514386

Methods for determining the refractory period and excitable gap during persistent atrial fibrillation in the goat.

M Duytschaever1, F Mast, M Killian, Y Blaauw, M Wijffels, M Allessie.   

Abstract

BACKGROUND: Recently, the temporal excitable gap during atrial fibrillation (AF) has been identified as a vulnerable parameter for cardioversion of AF. In this study, we evaluated 5 methods to measure the refractory period (RP(AF)) and the excitable period (EP(AF)) during persistent AF. METHODS AND
RESULTS: In 11 goats instrumented with 83 epicardial atrial electrodes, persistent AF (43+/-34 days) was induced with a median AF cycle length (CL) of 98+/-14 ms. To measure RP(AF), premature stimuli were applied to the center of the electrode array on the right or left atrium. The RP(AF) measured by mapping of premature stimuli was 70+/-12 ms ("gold standard"). The RP(AF) determined during entrainment of AF was 77+/-17 ms (R(2)=0.88, P<0.01). Statistical analysis of the effects of synchronized stimuli (each coupling interval x100) on the AFCL histogram yielded an RP(AF) of 70+/-13 ms (R(2)=0.94, P<0.01). A further simplification was to apply slow fixed-rate pacing (1 Hz) during AF. For each stimulus (n=250 to 500), the paced AFCL was plotted against its coupling interval, and capture was determined by statistical shortening of the AFCL (RP(AF) 71+/-17 ms, R(2)=0.84, P<0.01). The 5th percentile of the AFCL histogram as an index of RP(AF) was 77+/-12 ms (R(2)=0.90, P<0.01).
CONCLUSIONS: During persistent AF with an AFCL of 98+/-14 ms, the RP(AF) determined by mapping of synchronized premature stimuli (gold standard) was 70+/-12 ms, with an excitable period of 28+/-8 ms. Although the indirect methods to measure RP(AF) all correlated well with the gold standard, slow fixed-rate pacing seems to be the most attractive technique because of the ease of acquiring the data and the clear graphic result.

Entities:  

Mesh:

Year:  2001        PMID: 11514386     DOI: 10.1161/hc3401.093156

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  The pioneering work of George Mines on cardiac arrhythmias: groundbreaking ideas that remain influential in contemporary cardiac electrophysiology.

Authors:  Martin Aguilar; Stanley Nattel
Journal:  J Physiol       Date:  2016-01-19       Impact factor: 5.182

2.  Atrial fibrillation cycle length and atrial size in horses with and without recurrence of atrial fibrillation after electrical cardioversion.

Authors:  D De Clercq; A Decloedt; S U Sys; T Verheyen; N Van Der Vekens; G van Loon
Journal:  J Vet Intern Med       Date:  2014-02-24       Impact factor: 3.333

3.  The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models.

Authors:  Yuan Ji; Rosanne Varkevisser; Dragan Opacic; Alexandre Bossu; Marion Kuiper; Jet D M Beekman; Sihyung Yang; Azinwi Phina Khan; Dobromir Dobrev; Niels Voigt; Michael Zhuo Wang; Sander Verheule; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

4.  Effect of chronic exercise on myocardial electrophysiological heterogeneity and stability. Role of intrinsic cholinergic neurons: A study in the isolated rabbit heart.

Authors:  Luis Such-Miquel; Laia Brines; Antonio M Alberola; Manuel Zarzoso; Francisco J Chorro; Juan Guerrero; Germán Parra; Nathalia Gallego; Carlos Soler; Irene Del Canto; Antonio Guill; Luis Such
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

5.  Exploring Refractoriness as an Adjunctive Electrical Biomarker for Staging of Atrial Fibrillation.

Authors:  Lianne N van Staveren; Natasja M S de Groot
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

Review 6.  Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

Authors:  Alexander Burashnikov
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.